Login / Signup

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.

Paul A DiSilvestroSusana BanerjeeNicoletta ColomboGiovanni ScambiaByoung-Gie KimAna OakninMichael L FriedlanderAlla LisyanskayaAnne FloquetAlexandra LearyGabe S SonkeCharlie GourleyAmit M OzaAntonio Gonzáles MartinCarol AghajanianWilliam H BradleyCara A MathewsJoyce F LiuJohn McNamaraElizabeth S LoweMei-Lin Ah-SeeKathleen M Moorenull null
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Results indicate a clinically meaningful, albeit not statistically significant according to prespecified criteria, improvement in OS with maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation and support the use of maintenance olaparib to achieve long-term remission in this setting; the potential for cure may also be enhanced. No new safety signals were observed during long-term follow-up.
Keyphrases
  • newly diagnosed
  • clinical trial
  • study protocol
  • phase iii
  • breast cancer risk
  • rheumatoid arthritis
  • phase ii
  • human health
  • risk assessment
  • free survival
  • climate change
  • open label